About
Disulfican are a dedicated team of researchers creating an affordable treatment to tackle rare, aggressive and terminal cancers such as Malignant Mesothelioma (MM). Disulfican have developed a modified version of disulfiram, an existing licensed drug, so that it can reach and attack cancer tumours without degrading in the body.
A Growing Problem
UK MM Cases 2020
3300/yearUK MM Cases 2040
4950/yearMedian Survival
<24 months
People diagnosed with these diseases have very few treatment options and the hope is that our work will transform their prospects.
